Morgan Stanley Maintains Equal-Weight Rating on Humana
Morgan Stanley has recently reaffirmed an Equal-weight rating for Humana (NYSE: HUM) while setting a price target of $374.00 per share. This comes in light of concerning news regarding a decline in the number of members enrolled in 4+ Stars plans, as reported by the Centers for Medicare & Medicaid Services (CMS).
Significant Decline in 4+ Stars Enrollment
Humana announced that only about 1.6 million members, which equates to 25% of its total enrollment, will qualify for 4+ Stars plans. This marks a dramatic drop from 94% that was observed previously. The major contributor to this decline stems from the company's largest contract, identified as H5216, experiencing a decrease in rating from 4.5 Stars to 3.5 Stars.
Analyst Insights and Future Implications
The analysts at Morgan Stanley expressed concern, noting that this significant shift in enrollment was unexpected, raising questions regarding Humana's short-term outlook. They estimate that this change could impact earnings per share (EPS) for 2026 by approximately 90%, primarily due to the reduced affiliation with the higher Star-rated plans. In response, Humana has indicated its intention to evaluate potential strategies to alleviate the expected revenue challenges associated with the new 2025 Star ratings.
Review of CMS Data and Company Appeals
In reviewing CMS' preliminary data, Humana's management observed that the reduction in Star ratings might be linked to narrowly missing the higher industry benchmarks across several evaluation measures. The company has taken action, filing appeals with CMS, believing that there may be errors in the initial calculations.
Anticipated Results and Future Revenue Challenges
The complete results from CMS are set to be disclosed soon. Humana is also actively working on various strategies to address anticipated revenue impacts for 2026, acknowledging that its goal to achieve a Medicare Advantage margin of at least 3% by 2027 is now more uncertain than previously thought.
Comparative Analysis with Competitors
Furthermore, the analyst pointed out potential implications for other health companies, such as CVS Health (NYSE: CVS). It has been observed that CVS Health's key contracts seem to be performing better, which could benefit the company in a challenging market.
Current Standing of CVS Health
As indicated on the PlanFinder website, two of CVS' largest contracts are currently rated at 4.5/4 Stars and account for approximately 57% of their members, maintaining their status as 4+ Stars plans. The analysts postulate that should CVS experience a slight decrease in ratings, the anticipated impact on their 2026 EPS might be limited, around $0.13, translating to approximately 1.6%.
Understanding Humana's Market Position
Recent insights from market analysis provide a broader context for Humana’s situation. The company’s market capitalization is currently valued at about $28.87 billion with a P/E ratio of 16.36. This lower P/E ratio, alongside Humana's trading at a relatively modest revenue multiple, implies that the market may already be reflecting the worries around the recent drop in Star ratings.
Share Buybacks and Dividend History
InvestingPro notes that Humana has been actively repurchasing shares and has successfully maintained dividend payments for an impressive 14 consecutive years. These efforts are indicative of the management's confidence in the company's long-term viability, notwithstanding present challenges. Nonetheless, the stock has faced a notable downturn, with a month-to-date total return of -20.95% and a year-to-date decline of -38.48%.
Market Outlook and Profitability Predictions
Despite the setbacks, analysts are optimistic that Humana will maintain profitability within the current year. This aligns with the company’s strategies to manage the repercussions stemming from the drop in Star ratings on its revenue for 2026. For those interested in a more in-depth analysis, further insights are available, shedding light on Humana's financial standing and market dynamics.
Frequently Asked Questions
What rating did Morgan Stanley give Humana?
Morgan Stanley maintained an Equal-weight rating on Humana with a price target of $374.00.
What has caused the decline in Humana's Star ratings?
The decline is primarily due to Humana's largest contract falling from 4.5 Stars to 3.5 Stars according to the latest CMS assessment.
How does this affect Humana's earnings?
The expected impact on Humana's earnings per share for 2026 is approximately 90%, potentially leading to significant revenue challenges.
What steps is Humana taking in response to the ratings drop?
Humana is exploring various strategies to mitigate the expected revenue headwinds caused by the new Star ratings.
How does CVS Health compare in this situation?
CVS Health appears to be performing better with its key contracts, which may provide a more stable outlook compared to Humana's recent challenges.
